BRPI0908050A2 - Furo-e tieno[3,2-c]piridinas - Google Patents

Furo-e tieno[3,2-c]piridinas

Info

Publication number
BRPI0908050A2
BRPI0908050A2 BRPI0908050-3A BRPI0908050A BRPI0908050A2 BR PI0908050 A2 BRPI0908050 A2 BR PI0908050A2 BR PI0908050 A BRPI0908050 A BR PI0908050A BR PI0908050 A2 BRPI0908050 A2 BR PI0908050A2
Authority
BR
Brazil
Prior art keywords
furo
thieno
pyridines
Prior art date
Application number
BRPI0908050-3A
Other languages
English (en)
Inventor
Mark J Mulvihill
Jing Wang
Xin Chen
Ti Wang
An-Hu Li
Arno G Steinig
Andrew Kleinberg
Qinghua Weng
Hanqing Dong
Meizhong Jin
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0908050A2 publication Critical patent/BRPI0908050A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0908050-3A 2008-02-06 2009-02-06 Furo-e tieno[3,2-c]piridinas BRPI0908050A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6380008P 2008-02-06 2008-02-06
US11955308P 2008-12-03 2008-12-03
PCT/US2009/033311 WO2009100282A1 (en) 2008-02-06 2009-02-06 Furo-and thieno[3,2-c] pyridines

Publications (1)

Publication Number Publication Date
BRPI0908050A2 true BRPI0908050A2 (pt) 2015-08-11

Family

ID=40524808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908050-3A BRPI0908050A2 (pt) 2008-02-06 2009-02-06 Furo-e tieno[3,2-c]piridinas

Country Status (19)

Country Link
US (1) US8022206B2 (pt)
EP (1) EP2265616B8 (pt)
JP (1) JP2011511094A (pt)
KR (1) KR20110014971A (pt)
CN (1) CN102007127A (pt)
AR (1) AR070317A1 (pt)
AU (1) AU2009212338A1 (pt)
BR (1) BRPI0908050A2 (pt)
CA (1) CA2711078A1 (pt)
CL (1) CL2009000275A1 (pt)
EA (1) EA201070929A1 (pt)
ES (1) ES2451024T3 (pt)
IL (1) IL206758A0 (pt)
MX (1) MX2010008638A (pt)
PE (1) PE20091414A1 (pt)
TW (1) TW200944201A (pt)
UY (1) UY31638A1 (pt)
WO (1) WO2009100282A1 (pt)
ZA (1) ZA201005554B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8378104B2 (en) * 2010-02-11 2013-02-19 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
WO2011109593A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Substituted-5-aminopyrrolo/pyrazolopyridines
EP2566858A2 (en) * 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
US10614666B2 (en) 2011-04-20 2020-04-07 Video Gaming Technologies, Inc. Gaming machines with free play bonus mode presenting only winning outcomes
CA2887928A1 (en) 2011-10-31 2013-10-10 The Methodist Hospital Research Institute Compound comprising a mao targeting/seeker moiety for treating human gliomas
AU2013235487B2 (en) * 2012-03-23 2017-09-07 Memorial Sloan-Kettering Cancer Center Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
MX355943B (es) 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.
WO2015138925A1 (en) * 2014-03-14 2015-09-17 University Of Utah Research Foundation Ron inhibitors for use in preventing and treating bone loss
CN103923081B (zh) * 2014-04-14 2017-06-27 武汉光谷人福生物医药有限公司 化合物及其制备方法和应用
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN106866447A (zh) * 2017-03-30 2017-06-20 成都绿林科技有限公司 一种合成对乙酰基苯甲酰胺的方法
US10957159B2 (en) 2018-04-12 2021-03-23 Aristocrat Technologies Australia Pty Limited Gaming machine and method for displaying a free spin count-up
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
IL310653A (en) * 2021-08-10 2024-04-01 Jacobio Pharmaceuticals Co Ltd Compounds targeting mutant of p53
WO2024075696A1 (ja) 2022-10-03 2024-04-11 公立大学法人横浜市立大学 二環性構造を有するイミダゾピリジン誘導体
EP4635954A1 (en) * 2022-12-15 2025-10-22 Iregene Therapeutics Co., Ltd Inducer for inducing mesenchymal-epithelial transition and reprogramming

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100875380B1 (ko) 2001-06-23 2008-12-23 아벤티스 파마슈티칼스 인크. 단백질 키나제 억제제로서의 피롤로피리미딘
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
JP2006516626A (ja) 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
GEP20084341B (en) 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
WO2004100947A2 (en) * 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
NZ552946A (en) 2004-08-26 2010-09-30 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
MX2007012448A (es) * 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
KR100995790B1 (ko) * 2005-08-16 2010-11-22 에프. 호프만-라 로슈 아게 신규한 4-아미노-티에노[3,2-ｃ]피리딘-7-카르복실산아미드
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2009514899A (ja) * 2005-11-04 2009-04-09 スミスクライン ビーチャム コーポレーション チエノピリジンＢ−Ｒａｆキナーゼ阻害剤
RU2387650C2 (ru) 2005-12-05 2010-04-27 Пфайзер Продактс Инк. Полиморфы с-met/hgfr ингибитора
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
WO2007124181A2 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
KR101034351B1 (ko) 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
MX2010012290A (es) 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.

Also Published As

Publication number Publication date
EA201070929A1 (ru) 2011-04-29
ES2451024T3 (es) 2014-03-26
CL2009000275A1 (es) 2009-06-12
IL206758A0 (en) 2010-12-30
MX2010008638A (es) 2010-08-30
UY31638A1 (es) 2009-09-30
CN102007127A (zh) 2011-04-06
EP2265616B8 (en) 2014-01-08
JP2011511094A (ja) 2011-04-07
TW200944201A (en) 2009-11-01
US8022206B2 (en) 2011-09-20
PE20091414A1 (es) 2009-09-23
ZA201005554B (en) 2011-04-28
AU2009212338A1 (en) 2009-08-13
AR070317A1 (es) 2010-03-31
EP2265616A1 (en) 2010-12-29
EP2265616B1 (en) 2013-11-20
KR20110014971A (ko) 2011-02-14
WO2009100282A1 (en) 2009-08-13
CA2711078A1 (en) 2009-08-13
US20090197864A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
BRPI0908050A2 (pt) Furo-e tieno[3,2-c]piridinas
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
BRPI0914657A2 (pt) piridin-2-onae piridazin-3-onas substituídas
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
NO2021006I1 (no) Quofenix, delafloksacin
BRPI1006113A2 (pt) "derivado de piridina".
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
EP2272042A4 (en) SMART CAR COMPLETION
BRPI0914533A2 (pt) "métodos"
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
UY33125A (es) Diaza-espiro-[5,5]-undecanos
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0906357A2 (pt) Derivados de oxazepinopirimidona arilamida substituídos
EP2257169A4 (en) TETRAHYDROTHIENPYRIDINE
EP2239199A4 (en) Boarding bridge
BRPI0911625A2 (pt) Métodos
DE102008005493A8 (de) 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI1008173A2 (pt) "derivados de piridina espiroindolinona"
BRPI0922652A2 (pt) Derivados de quinazolinamida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2367 DE 17-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.